Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Rating of “Buy” from Brokerages

by · The Markets Daily

Royalty Pharma PLC (NASDAQ:RPRX – Get Free Report) has been given an average recommendation of “Buy” by the five brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $46.00.

RPRX has been the topic of several research analyst reports. The Goldman Sachs Group initiated coverage on shares of Royalty Pharma in a research report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target on the stock. Weiss Ratings cut shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Citigroup increased their price target on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, July 22nd. Wall Street Zen raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Morgan Stanley reduced their price target on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th.

Check Out Our Latest Analysis on RPRX

Hedge Funds Weigh In On Royalty Pharma

Large investors have recently bought and sold shares of the business. USA Financial Formulas bought a new position in Royalty Pharma in the second quarter worth about $32,000. Financial Consulate Inc. bought a new position in Royalty Pharma in the third quarter worth about $35,000. Summit Securities Group LLC bought a new position in Royalty Pharma in the first quarter worth about $36,000. WPG Advisers LLC bought a new position in Royalty Pharma in the first quarter worth about $39,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in Royalty Pharma by 42.1% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,358 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 402 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Up 1.6%

Shares of Royalty Pharma stock opened at $37.54 on Tuesday. The business has a 50-day moving average of $36.19 and a 200-day moving average of $35.22. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.26 and a quick ratio of 1.26. The company has a market capitalization of $21.89 billion, a PE ratio of 21.70, a P/E/G ratio of 2.06 and a beta of 0.60. Royalty Pharma has a 1-year low of $24.05 and a 1-year high of $38.00.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.04. The company had revenue of $578.67 million during the quarter, compared to the consensus estimate of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. As a group, equities analysts forecast that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $0.88 annualized dividend and a dividend yield of 2.3%. Royalty Pharma’s dividend payout ratio (DPR) is presently 50.87%.

About Royalty Pharma

(Get Free Report)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

See Also